Invesco Ltd. Boosts Stake in Cellebrite DI Ltd. $CLBT

Key Points

• Invesco Ltd. increased its holdings in Cellebrite DI Ltd. by 122.1% in the first quarter, now owning approximately 3.3 million shares valued at about $64 million.
• Cellebrite DI recently reported $113.28 million in revenue for the quarter, exceeding analysts' expectations, and achieved an earnings per share (EPS) of $0.12, beating predictions by $0.01.
• Multiple analysts have adjusted their price ratings for Cellebrite DI, with the average price target lowered to $22.40, while maintaining a consensus rating of "Buy."

Invesco Ltd. boosted its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 122.1% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,296,079 shares of the company's stock after buying an additional 1,811,757 shares during the quarter. Invesco Ltd. owned 1.38% of Cellebrite DI worth $64,043,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of CLBT. Swiss National Bank grew its position in shares of Cellebrite DI by 27.0% during the 1st quarter. Swiss National Bank now owns 191,300 shares of the company's stock worth $3,717,000 after buying an additional 40,700 shares in the last quarter. US Bancorp DE bought a new position in shares of Cellebrite DI during the 1st quarter worth $308,000. Natixis Advisors LLC bought a new position in shares of Cellebrite DI during the 1st quarter worth $469,000. XTX Topco Ltd grew its position in shares of Cellebrite DI by 37.2% during the 1st quarter. XTX Topco Ltd now owns 35,095 shares of the company's stock worth $682,000 after buying an additional 9,518 shares in the last quarter. Finally, TD Asset Management Inc lifted its stake in shares of Cellebrite DI by 909.6% during the 1st quarter. TD Asset Management Inc now owns 106,306 shares of the company's stock worth $2,066,000 after purchasing an additional 95,777 shares during the last quarter. Hedge funds and other institutional investors own 45.88% of the company's stock.

Cellebrite DI Price Performance

CLBT stock traded down $0.27 during trading on Wednesday, hitting $15.53. The stock had a trading volume of 847,760 shares, compared to its average volume of 1,668,759. The company's 50-day moving average price is $14.96 and its two-hundred day moving average price is $17.67. Cellebrite DI Ltd. has a twelve month low of $13.10 and a twelve month high of $26.30. The stock has a market capitalization of $3.72 billion, a P/E ratio of -20.43, a PEG ratio of 3.20 and a beta of 1.27.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last released its earnings results on Thursday, August 14th. The company reported $0.12 earnings per share for the quarter, topping analysts' consensus estimates of $0.11 by $0.01. The business had revenue of $113.28 million for the quarter, compared to analyst estimates of $112.33 million. Cellebrite DI had a negative net margin of 34.56% and a positive return on equity of 23.92%. The business's revenue was up 18.4% on a year-over-year basis. During the same period last year, the company posted $0.10 EPS. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, sell-side analysts expect that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. Wall Street Zen upgraded Cellebrite DI from a "hold" rating to a "buy" rating in a research note on Saturday. JPMorgan Chase & Co. reduced their target price on Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating on the stock in a research report on Monday, May 12th. Lake Street Capital reduced their target price on Cellebrite DI from $24.00 to $22.00 and set a "buy" rating on the stock in a research report on Friday, August 15th. Finally, Needham & Company LLC dropped their price target on Cellebrite DI from $24.00 to $18.00 and set a "buy" rating on the stock in a research note on Thursday, August 14th. Five analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $22.40.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.